Brian Taylor Slingsby net worth and biography

Brian Slingsby Biography and Net Worth

Director of Mineralys Therapeutics

Brian Taylor “BT” Slingsby, M.D., Ph.D., M.P.H. founded Mineralys in 2019 and has served on our board of directors since that time. Dr. Slingsby is Founder & Managing Director at Catalys Pacific. In addition to serving as founding CEO and former Executive Chairman of Mineralys, he has served as the founding CEO and subsequent Executive Chairman of Pathalys Pharma, Crystalys Therapeutics, Kirilys Therapeutics, Accelys Pharma, Aculys Pharma, Hepalys Pharma, and Renalys Pharma. Prior to Catalys Pacific, he founded and served as CEO and Executive Director of the Global Health Innovative Technology (GHIT) Fund – the world’s first public-private fund focused on the development of new medicines for low- and middle-income countries. Previously, he was an executive at Eisai Co. & Ltd following his time in academia.

Dr. Slingsby graduated from Brown University with honors, earned his MPH and Ph.D. from Kyoto University and the University of Tokyo, and received his MD with honors from the George Washington University. An author on over 50 peer-reviewed articles on medicine and public health, he formerly served as a Visiting Professor at Keio University, Kyoto University and Osaka University and Visiting Research Fellow at the University of Tokyo.

What is Brian Taylor Slingsby's net worth?: The estimated net worth of Brian Taylor Slingsby is at least $261.14 million as of November 20th, 2025. Slingsby owns 7,903,838 shares of Mineralys Therapeutics stock worth more than $261,142,808 as of January 27th. This net worth evaluation does not reflect any other investments that Slingsby may own. Additionally, Slingsby receives a salary of $69,330.00 as Director at Mineralys Therapeutics. Learn More about Brian Taylor Slingsby's net worth.
How old is Brian Taylor Slingsby?: Slingsby is currently 47 years old. There are 3 older executives and no younger executives at Mineralys Therapeutics. The oldest executive at Mineralys Therapeutics is Dr. David M. Rodman M.D., Chief Medical Officer, who is 69 years old. Learn More on Brian Taylor Slingsby's age.
What is Brian Taylor Slingsby's salary?: As the Director of Mineralys Therapeutics, Inc., Slingsby earns $69,330.00 per year. There are 3 executives that earn more than Slingsby. The highest earning executive at Mineralys Therapeutics is Mr. Jon Congleton, CEO & Director, who commands a salary of $775,770.00 per year. Learn More on Brian Taylor Slingsby's salary.
How do I contact Brian Taylor Slingsby?: The corporate mailing address for Slingsby and other Mineralys Therapeutics executives is , , . Mineralys Therapeutics can also be reached via phone at 888-378-6240 and via email at [email protected]. Learn More on Brian Taylor Slingsby's contact information.
Has Brian Taylor Slingsby been buying or selling shares of Mineralys Therapeutics?: Brian Taylor Slingsby has not been actively trading shares of Mineralys Therapeutics during the last ninety days. Most recently, Brian Taylor Slingsby sold 1,000,000 shares of the business's stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $43.35, for a transaction totalling $43,350,000.00. Following the completion of the sale, the director now directly owns 7,903,838 shares of the company's stock, valued at $342,631,377.30. Learn More on Brian Taylor Slingsby's trading history.
Who are Mineralys Therapeutics' active insiders?: Mineralys Therapeutics' insider roster includes Srinivas Akkaraju (Director), Jon Congleton (CEO), Alexander Gold (Director), Daphne Karydas (Director), Adam Levy (Chief Financial Officer), David Rodman (Chief Medical Officer), and Brian Slingsby (Director). Learn More on Mineralys Therapeutics' active insiders.
Are insiders buying or selling shares of Mineralys Therapeutics?: In the last twelve months, Mineralys Therapeutics insiders bought shares 4 times. They purchased a total of 3,661,001 shares worth more than $70,599,973.50. In the last twelve months, insiders at the sold shares 32 times. They sold a total of 1,962,179 shares worth more than $76,380,609.84. The most recent insider tranaction occured on January, 20th when insider David Malcom Rodman sold 416 shares worth more than $13,353.60. Insiders at Mineralys Therapeutics own 33.2% of the company. Learn More about insider trades at Mineralys Therapeutics.
Information on this page was last updated on 1/20/2026.

Brian Taylor Slingsby Insider Trading History at Mineralys Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/20/2025	Sell	1,000,000	$43.35	$43,350,000.00	7,903,838
7/24/2024	Sell	550,000	$13.05	$7,177,500.00	8,644,579

Brian Taylor Slingsby Buying and Selling Activity at Mineralys Therapeutics

Mineralys Therapeutics Company Overview

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Today's Range

Now: $33.04

$32.05

$33.26

50 Day Range

MA: $36.95

$31.31

$43.39

2 Week Range

Now: $33.04

$8.24

$47.65

Volume

682,940 shs

Average Volume

1,165,937 shs

Market Capitalization

$2.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Brian Slingsby Biography and Net Worth

What is Brian Taylor Slingsby's net worth?

How old is Brian Taylor Slingsby?

What is Brian Taylor Slingsby's salary?

How do I contact Brian Taylor Slingsby?

Has Brian Taylor Slingsby been buying or selling shares of Mineralys Therapeutics?

Who are Mineralys Therapeutics' active insiders?

Are insiders buying or selling shares of Mineralys Therapeutics?